Author

A. Menge

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Research Focus:cell type annotation· 2 Research Focus:benchmarking· 1 Research Focus:differential expression· 1 Approach:microscopy & imaging analysis· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

S. Knapp· 4 shared S. Mueller· 4 shared L. Elson· 3 shared A. C. Joerger· 2 shared A. Kaiser· 2 shared A. Kraemer· 2 shared B.-T. Berger· 2 shared D.-I. Balourdas· 2 shared

Activity by Year

2023-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

S. Knapp

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Functional characterization of pathway inhibitors for the ubiquitin-proteasome system (UPS) as tool compounds for CRBN and VHL-mediated targeted protein degradation

M. P. Schwalm, A. Menge, L. Elson, F. A. Greco, M. B. Robers, S. Mueller, S. Knapp

The paper evaluates diverse ubiquitin pathway inhibitors as controls for CRBN and VHL-mediated protein degradation, assessing their potency and toxicity using the HiBiT system and high content assays.

bioRxiv · Jun 12, 2024Biochemistry

Development of selective pyridopyrimidin-7(8H)-one-based Mammalian STE20-like (MST3/4) kinase inhibitors

M. Rak, A. Menge, R. Tesch, L. M. Berger, D.-I. Balourdas, E. Shevchenko, A. Kraemer, L. Elson, B.-T. Berger, I. Abdi, L. M. Wahl, A. Poso, A. Kaiser, T. Hanke, T. Kronenberger, , S. Knapp

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

bioRxiv · Nov 24, 2023Biochemistry

Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3

J. A. Amrhein, L. M. Berger, D.-I. Balourdas, A. C. Joerger, A. Menge, A. Kraemer, J. M. Frischkorn, B.-T. Berger, L. Elson, A. Kaiser, M. Schubert-Zsilavecz, S. Mueller, S. Knapp, T. Hanke

The paper designs and synthesizes a macrocyclic inhibitor, JA310, that selectively targets MST3 with high potency and kinome-wide selectivity.

bioRxiv · Oct 20, 2023Biochemistry

Discovery of a new activator of Slack potassium channels with robust efficacy in models of histamine-independent and chronic itch

A. Balzulat, W. F. Zhu, C. Flauaus, V. Hernandez-Olmos, J. Heering, S. Sethumadhavan, M. Dubiel, A. Frank, A. Menge, M. Hebchen, K. Metzner, R. Lu, R. Lukowski, P. Ruth, S. Knapp, , A. Schmidtko

This study identifies compound 6 as a potent Slack potassium channel activator effective in treating histamine-independent and chronic itch without motor side effects.

bioRxiv · Oct 5, 2023 · PreprintPharmacology & Toxicology